International Clinical Trial: A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination with PD-(L)1 Monoclonal Antibody in Patients with Advanced Malignant Solid Tumors

Geneva, June 22 -- International Clinical Trials Registry received information related to the study (ChiCTR2600126590) titled 'A Phase I/II Clinical Study Evaluating the Safety, Tolerability, and Efficacy of N-3C01 as Monotherapy and in Combination with PD-(L)1 Monoclonal Antibody in Patients with Advanced Malignant Solid Tumors' on June 11.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Shanghai East Hospital

Condition: Solid Tumors

Intervention: Phase I Dose Group 1:1mcg/kg, Q2W Phase I Dose Group 2:3mcg/kg, Q2W Phase I Dose Group 3:10mcg/kg, Q2W Phase I Dose Group 4:20mcg/kg, Q2W Phase I Dose Group 5:30mcg/kg, Q2W Phase I Dose Group 6:30mcg/kg, Q3W Phase I Dose Group 7:30mcg/kg, Q3W Phase I Dose Grou...